GSK tosses a trio of clinical-stage drugs on trial failures, winnowing out its respiratory pipeline as cancer moves to center stage

GlaxoSmithKline is sweeping out three of its clinical stage programs as it continues to winnow out the weak from the strong in the pipeline. And there’s no surprise to see that respiratory is taking the big hit here.